References
- Jagasia MH, Greinix HT, Arora M, et al. National institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: i. The 2014 diagnosis and staging working group report. Biol Blood Marrow Transplant. 2015;21(3):389–401e1. doi:https://doi.org/10.1016/j.bbmt.2014.12.001.
- Shulman HM, Sullivan KM, Weiden PL, et al. Chronic graft-versus-host syndrome in man: a long-term clinicopathologic study of 20 Seattle patients. Am J Med. 1980;69(2):204–217. doi:https://doi.org/10.1016/0002-9343(80)90380-0.
- Filipovich AH, Weisdorf D, Pavletic S, et al. National institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: i. Diagnosis and staging working group report. Biol Blood Marrow Transplant. 2005;11(12):945–956. doi:https://doi.org/10.1016/j.bbmt.2005.09.004.
- Lee SJ. Classification systems for chronic graft-versus-host disease. Blood. 2017;129(1):30–37. doi:https://doi.org/10.1182/blood-2016-07-686642.
- Pavletic SZ, Vogelsang GB, Lee SJ. 2014 national institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: preface to the series. Biol Blood Marrow Transplant. 2015;21(3):387–388. doi:https://doi.org/10.1016/j.bbmt.2014.12.035.
- Hasanain Shikari FA, Dana R, Dana R, Dana R. Onset of ocular graft-versus-host disease symptoms after allogeneic hematopoietic stem cell transplantation. Cornea. 2015;34(3):243. doi:https://doi.org/10.1097/ICO.0000000000000340.
- Jacobs R, Tran U, Chen H, et al. Prevalence and risk factors associated with development of ocular GVHD defined by NIH consensus criteria. Bone Marrow Transplant. 2012;47(11):1470–1473. doi:https://doi.org/10.1038/bmt.2012.56.
- Saboo US, Amparo F, Abud TB, et al. Vision-related quality of life in patients with ocular graft-versus-host disease. Ophthalmology. 2015;122(8):1669–1674. doi:https://doi.org/10.1016/j.ophtha.2015.04.011.
- Hong Y-Q, Wan B, Li X-F. Macrophage regulation of graft-vs-host disease. World J Clin Cases. 2020;8(10):1793. doi:https://doi.org/10.12998/wjcc.v8.i10.1793.
- Welniak LA, Blazar BR, Murphy WJ. Immunobiology of allogeneic hematopoietic stem cell transplantation. Annu Rev Immunol. 2007;25:139–170. doi:https://doi.org/10.1146/annurev.immunol.25.022106.141606.
- Shikari H, Antin JH, Dana R. Ocular graft-versus-host disease: a review. Surv Ophthalmol. 2013;58(3):233–251. doi:https://doi.org/10.1016/j.survophthal.2012.08.004.
- Milosevic S, Bachnick B, Karim K, et al. Identification of MHC II-restricted minor histocompatibility antigens after HLA-identical stem-cell transplantation. Transplantation. 2010;90(9):1030–1035. doi:https://doi.org/10.1097/TP.0b013e3181f5470c.
- Kawase T, Morishima Y, Matsuo K, et al. High-risk HLA allele mismatch combinations responsible for severe acute graft-versus-host disease and implication for its molecular mechanism. Blood. 2007;110(7):2235–2241. doi:https://doi.org/10.1182/blood-2007-02-072405.
- Goulmy E, Schipper R, Pool J, et al. Mismatches of minor histocompatibility antigens between HLA-identical donors and recipients and the development of graft-versus-host disease after bone marrow transplantation. N Engl J Med. 1996;334(5):281–285. doi:https://doi.org/10.1056/NEJM199602013340501.
- De Bueger M, Bakker A, Van Rood JJ, et al. Tissue distribution of human minor histocompatibility antigens. Ubiquitous versus restricted tissue distribution indicates heterogeneity among human cytotoxic T lymphocyte-defined non-MHC antigens. J Immunol. 1992;149(5):1788–1794.
- Couriel D, Caldera H, Champlin R, et al. Acute graft‐versus‐host disease: pathophysiology, clinical manifestations, and management. Cancer. 2004;101(9):1936–1946. doi:https://doi.org/10.1002/cncr.20613.
- Reddy P, Ferrara JLM. Immunobiology of acute graft-versus-host disease. Blood Rev. 2003;17(4):187–194. doi:https://doi.org/10.1016/S0268-960X(03)00009-2.
- Antin J, Ferrara J, Cytokine dysregulation and acute graft-versus-host disease. 1992.
- Ferrara JL, Antin JH. The pathophysiology of graft‐versus‐host disease. Thomas’ Hematopoietic Cell Transplant. 2015;1:146–155.
- Hill GR, Crawford JM, Cooke KR, et al. Total body irradiation and acute graft-versus-host disease: the role of gastrointestinal damage and inflammatory cytokines. Blood J American Soc Hematol. 1997;90(8):3204–3213. PMID:9376604.
- Cooke KR, Hill GR, Crawford JM, et al. Tumor necrosis factor-alpha production to lipopolysaccharide stimulation by donor cells predicts the severity of experimental acute graft-versus-host disease. J Clin Invest. 1998;102(10):1882–1891. doi:https://doi.org/10.1172/JCI4285.
- Xun CQ, Thompson JS, Jennings CD, Brown SA, Widmer MB. Effect of Total Body Irradiation, Busulfan-cyclophosphamide, or Cyclophosphamide Conditioning on Inflammatory Cytokine Release and Development of Acute and Chronic Graft-versus-host Disease in H-2-incompatible Transplanted SCID Mice. Blood. 1994;83(8):2360–7. PMID:8161803.
- Shlomchik WD, Couzens MS, Tang CB, et al. Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science. 1999;285(5426):412–415. doi:https://doi.org/10.1126/science.285.5426.412.
- Dustin ML. Role of adhesion molecules in activation signaling in T lymphocytes. J Clin Immunol. 2001;21(4):258–263. doi:https://doi.org/10.1023/A:1010927208180.
- Shlomchik WD. Antigen presentation in graft-vs-host disease. Exp Hematol. 2003;31(12):1187–1197. doi:https://doi.org/10.1016/j.exphem.2003.09.017.
- Sharpe AH, Freeman GJ. The B7–CD28 superfamily. Nat Rev Immunol. 2002;2(2):116–126. doi:https://doi.org/10.1038/nri727.
- Korngold R, Sprent J. T cell subsets and graft-versus-host disease. Transplantation. 1987;44(3):335–339. doi:https://doi.org/10.1097/00007890-198709000-00002.
- Brown GR, Lee E, Thiele DL. TNF-TNFR2 interactions are critical for the development of intestinal graft-versus-host disease in MHC class II-disparate (C57BL/6J→ C57BL/6J× bm12) F1 mice. J Immunol. 2002;168(6):3065–3071. doi:https://doi.org/10.4049/jimmunol.168.6.3065.
- Piguet P-F, Grau GE, Allet B, et al. Tumor necrosis factor/cachectin is an effector of skin and gut lesions of the acute phase of graft-vs.-host disease. J Exp Med. 1987;166(5):1280–1289. doi:https://doi.org/10.1084/jem.166.5.1280.
- Ferrara JLM, Krenger W. Graft-versus-host disease: the influence of type 1 and type 2 T cell cytokines. Transfus Med Rev. 1998;12(1):1–17. doi:https://doi.org/10.1016/S0887-7963(98)80085-0.
- Ferrara JL, Levine JE, Reddy P, et al. Graft-versus-host disease. Lancet. 2009;373(9674):1550–1561. doi:https://doi.org/10.1016/S0140-6736(09)60237-3.
- Cohen JL, Boyer O. The role of CD4+ CD25hi regulatory T cells in the physiopathogeny of graft-versus-host disease. Curr Opin Immunol. 2006;18(5):580–585. doi:https://doi.org/10.1016/j.coi.2006.07.007.
- Bastian D, Wu Y, Betts BC, et al. The IL-12 cytokine and receptor family in graft-vs.-host disease. Front Immunol. 2019;10:988. doi:https://doi.org/10.3389/fimmu.2019.00988.
- Lawley TJ, Peck GL, Moutsopoulos HM, Gratwohl AA, Deisseroth AB. Scleroderma, Sjögren-like syndrome, and chronic graft-versus-host disease. Ann Intern Med. 1977;87(6):707–709. doi:https://doi.org/10.7326/0003-4819-87-6-707.
- Holländer G, Widmer B, Burakoff S. Loss of normal thymic repertoire selection and persistence of autoreactive T cells in graft vs host disease. J Immunol. 1994;152:1609–1617.
- Soiffer R. T Cell Depletion to Prevent Graft-vs-host Disease, in Thomas’ Hematopoietic Cell Transplantation. Blackwell: Oxford; 2008:221–233.
- Bacigalupo A, Lamparelli T, Barisione G, et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biol Blood Marrow Transplant. 2006;12(5):560–565. doi:https://doi.org/10.1016/j.bbmt.2005.12.034.
- Beres A, Drobyski W. The role of regulatory T cells in the biology of graft versus host disease. Front Immunol. 2013;4:163. doi:https://doi.org/10.3389/fimmu.2013.00163.
- Soiffer R. Immune modulation and chronic graft-versus-host disease. Bone Marrow Transplant. 2008;42(1):S66–S69. doi:https://doi.org/10.1038/bmt.2008.119.
- She K, Gilman AL, Aslanian S, et al. Altered Toll-like receptor 9 responses in circulating B cells at the onset of extensive chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2007;13(4):386–397. doi:https://doi.org/10.1016/j.bbmt.2006.12.441.
- Miklos DB, Kim HT, Miller KH, et al. Antibody responses to HY minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission. Blood. 2005;105(7):2973–2978. doi:https://doi.org/10.1182/blood-2004-09-3660.
- Sarantopoulos S, Stevenson KE, Kim HT, et al. Altered B-cell homeostasis and excess BAFF in human chronic graft-versus-host disease. Blood J American Soc Hematol. 2009;113(16):3865–3874. doi:https://doi.org/10.1182/blood-2008-09-177840.
- Cutler C, Miklos D, Kim HT, et al. Rituximab for steroid-refractory chronic graft-versus-host disease. Blood. 2006;108(2):756–762. doi:https://doi.org/10.1182/blood-2006-01-0233.
- Ogawa Y, Kuwana M, Yamazaki K, et al. Periductal area as the primary site for T-cell activation in lacrimal gland chronic graft-versus-host disease. Invest Ophthalmol Vis Sci. 2003;44(5):1888–1896. doi:https://doi.org/10.1167/iovs.02-0699.
- Ogawa Y, Yamazaki K, Kuwana M, et al. A significant role of stromal fibroblasts in rapidly progressive dry eye in patients with chronic GVHD. Invest Ophthalmol Vis Sci. 2001;42(1):111–119. PMID:11133855.
- Ogawa Y, Kuwana M. Dry eye as a major complication associated with chronic graft-versus-host disease after hematopoietic stem cell transplantation. Cornea. 2003;22(7):S19–S27. doi:https://doi.org/10.1097/00003226-200310001-00004.
- Arafat SN, Robert M-C, Abud T, et al. Elevated neutrophil elastase in tears of ocular graft-versus-host disease patients. Am J Ophthalmol. 2017;176:46–52. doi:https://doi.org/10.1016/j.ajo.2016.12.026.
- Nair S, Vanathi M, Mahapatra M, et al. Tear inflammatory mediators and protein in eyes of post allogenic hematopoeitic stem cell transplant patients. Ocul Surf. 2018;16(3):352–367. doi:https://doi.org/10.1016/j.jtos.2018.04.007.
- Cocho L, Fernández I, Calonge M, et al. Biomarkers in ocular chronic graft versus host disease: tear cytokine-and chemokine-based predictive model. Invest Ophthalmol Vis Sci. 2016;57(2):746–758. doi:https://doi.org/10.1167/iovs.15-18615.
- Kusne Y, Temkit M, Khera N, et al. Conjunctival subepithelial fibrosis and meibomian gland atrophy in ocular graft-versus-host disease. Ocul Surf. 2017;15(4):784–788. doi:https://doi.org/10.1016/j.jtos.2017.08.002.
- Jabs DA, Wingard J, Green WR, et al. The eye in bone marrow transplantation: III. Conjunctival graft-vs-host disease. Arch Ophthalmol. 1989;107(9):1343–1348. doi:https://doi.org/10.1001/archopht.1989.01070020413046.
- Pérez RL, Pérez-Simón JA, Caballero-Velazquez T, et al. Limbus damage in ocular graft-versus-host disease. Biol Blood Marrow Transplant. 2011;17(2):270–273. doi:https://doi.org/10.1016/j.bbmt.2010.08.008.
- Kheirkhah A, Rahimi Darabad R, Cruzat A, et al. Corneal epithelial immune dendritic cell alterations in subtypes of dry eye disease: a pilot in vivo confocal microscopic study. Invest Ophthalmol Vis Sci. 2015;56(12):7179–7185. doi:https://doi.org/10.1167/iovs.15-17433.
- Kheirkhah A, Qazi Y, Arnoldner MA, et al. In vivo confocal microscopy in dry eye disease associated with chronic graft-versus-host disease. Invest Ophthalmol Vis Sci. 2016;57(11):4686–4691. doi:https://doi.org/10.1167/iovs.16-20013.
- He J, Park S-Y, Nishio T, et al. In vivo confocal microscopy evaluation of ocular surface with graft-versus-host disease-related dry eye disease. Sci Rep. 2017;7(1):1–10. doi:https://doi.org/10.1038/s41598-016-0028-x.
- Nassiri N, Eslani M, Panahi N, et al. Ocular graft versus host disease following allogeneic stem cell transplantation: a review of current knowledge and recommendations. J Ophthalmic Vis Res. 2013;8(4):351–8. PMID:24653823.
- Na K, Yoo Y-S, Mok JW, et al. Incidence and risk factors for ocular GVHD after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2015;50(11):1459–1464. doi:https://doi.org/10.1038/bmt.2015.187.
- Pellegrini M, Bernabei F, Barbato F, et al. Incidence, risk factors and complications of ocular graft-versus-host disease following hematopoietic stem cell transplantation: incidence, risk factors and complications of ocular GVHD. Am J Ophthalmol. 2021;227:25–34. doi:https://doi.org/10.1016/j.ajo.2021.02.022.
- Appenteng Osae E, Steven P. Meibomian gland dysfunction in ocular graft vs. host disease: a need for pre-clinal models and deeper insights. Int J Mol Sci. 2021;22(7):3516. doi:https://doi.org/10.3390/ijms22073516.
- Liu CY,Francis JH, Pulido JS, Abramson DH. Ocular side effects of systemically administered chemotherapy. In: Hesketh PJ, Gardiner MF, eds. UpToDate. Waltham, MA: UpToDate; 2018.
- Rodrigues KS, Oliveira-Ribeiro C, de Abreu Fiuza Gomes S, et al. Cutaneous graft-versus-host disease: diagnosis and treatment. Am J Clin Dermatol. 2018;19(1):33–50. doi:https://doi.org/10.1007/s40257-017-0306-9.
- Gomes JAP, Azar DT, Baudouin C, et al. TFOS DEWS II iatrogenic report. Ocul Surf. 2017;15(3):511–538. doi:https://doi.org/10.1016/j.jtos.2017.05.004.
- Ogawa Y, Kim SK, Dana R, et al. International chronic ocular graft-vs-host-disease (GVHD) consensus group: proposed diagnostic criteria for chronic GVHD (Part I). Sci Rep. 2013;3(1):3419. doi:https://doi.org/10.1038/srep03419.
- Rapoport Y, Freeman T, Koyama T, et al. Validation of international chronic ocular graft-versus-host disease (GVHD) group diagnostic criteria as a chronic ocular GVHD-specific metric. Cornea. 2016;36(2):258–263. doi:https://doi.org/10.1097/ICO.0000000000001109.
- Okumura Y, Inomata T, Iwata N, et al. A review of dry eye questionnaires: measuring patient-reported outcomes and health-related quality of life. Diagnostics. 2020;10(8):559. doi:https://doi.org/10.3390/diagnostics10080559.
- Pathak M, Diep PP, Lai X, et al. Ocular findings and ocular graft-versus-host disease after allogeneic stem cell transplantation without total body irradiation. Bone Marrow Transplant. 2018;53(7):863–872. doi:https://doi.org/10.1038/s41409-018-0090-z.
- Amparo F, Shikari H, Saboo U, et al. Corneal fluorescein staining and ocular symptoms but not Schirmer test are useful as indicators of response to treatment in chronic ocular GVHD. Ocul Surf. 2018;16(3):377–381. doi:https://doi.org/10.1016/j.jtos.2018.05.002.
- Inamoto Y, Chai X, Kurland BF, et al. Validation of measurement scales in ocular graft-versus-host disease. Ophthalmology. 2012;119(3):487–493. doi:https://doi.org/10.1016/j.ophtha.2011.08.040.
- Ogawa Y, Okamoto S, Wakui M, et al. Dry eye after haematopoietic stem cell transplantation. British J Ophthalmol. 1999;83(10):1125–1130. doi:https://doi.org/10.1136/bjo.83.10.1125.
- Ban Y, Ogawa Y, Ibrahim OMA, et al. Morphologic evaluation of meibomian glands in chronic graft-versus-host disease using in vivo laser confocal microscopy. Mol Vis. 2011;17:2533.
- He J, Yamane M, Shibata S, et al. Ocular surface and tear film characteristics in a sclerodermatous chronic graft-versus-host disease mouse model. Cornea. 2018;37(4):486–494. doi:https://doi.org/10.1097/ICO.0000000000001487.
- Giannaccare G, Bernabei F, Pellegrini M, et al. Eyelid metrics assessment in patients with chronic ocular graft versus-host disease. Ocul Surf. 2019;17(1):98–103. doi:https://doi.org/10.1016/j.jtos.2018.10.005.
- Kheirkhah A, Coco G, Satitpitakul V, et al. Subtarsal fibrosis is associated with ocular surface epitheliopathy in graft-versus-host disease. Am J Ophthalmol. 2018;189:102–110. doi:https://doi.org/10.1016/j.ajo.2018.02.020.
- Robinson M, Lee SS, Rubin BI, et al. Topical corticosteroid therapy for cicatricial conjunctivitis associated with chronic graft-versus-host disease. Bone Marrow Transplant. 2004;33(10):1031–1035. doi:https://doi.org/10.1038/sj.bmt.1704453.
- Hosseini H, Kumar PV, Geramizadeh B, et al. Conjunctival scrape cytology findings in patients with chronic graft-versus-host disease following allogeneic bone marrow transplantation. Acta Cytol. 2010;54(3):272–276. doi:https://doi.org/10.1159/000325034.
- Cher I. Superior limbic keratoconjunctivitis: multifactorial mechanical pathogenesis. Clin Exp Ophthalmol. 2000;28(3):181–184. doi:https://doi.org/10.1046/j.1442-9071.2000.00284.x.
- Nassar A, Tabbara KF, Aljurf M. Ocular manifestations of graft-versus-host disease. Saudi J Ophthalmol. 2013;27(3):215–222. doi:https://doi.org/10.1016/j.sjopt.2013.06.007.
- Sinha S, Singh RB, Dohlman TH, et al. Prevalence of persistent corneal epithelial defects in chronic ocular graft-versus-host disease. Am J Ophthalmol. 2020;218:296–303. doi:https://doi.org/10.1016/j.ajo.2020.05.035.
- Stevenson W, Shikari H, Saboo U, et al. Bilateral corneal ulceration in ocular graft-versus-host disease. Clin Ophthalmol. 2013;7:2153. doi:https://doi.org/10.2147/OPTH.S51180.
- Carpenter PA, Kitko CL, Elad S, et al. National institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: v. The 2014 ancillary therapy and supportive care working group report. Biol Blood Marrow Transplant. 2015;21(7):1167–1187. doi:https://doi.org/10.1016/j.bbmt.2015.03.024.
- Stewart BL, Storer B, Storek J, et al. Duration of immunosuppressive treatment for chronic graft-versus-host disease. Blood. 2004;104(12):3501–3506. doi:https://doi.org/10.1182/blood-2004-01-0200.
- Lee SJ, Wolff D, Kitko C, et al. Measuring therapeutic response in chronic graft-versus-host disease. National institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: IV. The 2014 response criteria working group report. Biol Blood Marrow Transplant. 2015;21(6):984–999. doi:https://doi.org/10.1016/j.bbmt.2015.02.025.
- Sabti S, Halter JP, Braun Fränkl BC, et al. Punctal occlusion is safe and efficient for the treatment of keratoconjunctivitis sicca in patients with ocular GvHD. Bone Marrow Transplant. 2012;47(7):981–984. doi:https://doi.org/10.1038/bmt.2011.205.
- Wang Y, Carreno-Galeano JT, Singh RB, et al. Long-term outcomes of punctal cauterization in the management of ocular surface diseases. Cornea. 2021;40(2):168–171. doi:https://doi.org/10.1097/ICO.0000000000002384.
- Satchi K, McNab AA. Conjunctival cicatrizing disease presenting with lacrimal obstruction. Orbit. 2016;35(6):321–323. doi:https://doi.org/10.1080/01676830.2016.1193539.
- Yin J, Kheirkhah A, Dohlman T, et al. Reduced efficacy of low-dose topical steroids in dry eye disease associated with graft-versus-host disease. Am J Ophthalmol. 2018;190:17–23. doi:https://doi.org/10.1016/j.ajo.2018.03.024.
- Smith V, Cook S. Doxycycline—a role in ocular surface repair. British J Ophthalmol. 2004;88(5):619–625. doi:https://doi.org/10.1136/bjo.2003.025551.
- Kiang E, Tesavibul N, Yee R, et al. The use of topical cyclosporin A in ocular graft-versus-host-disease. Bone Marrow Transplant. 1998;22(2):147–151. doi:https://doi.org/10.1038/sj.bmt.1701304.
- Barber LD, Pflugfelder SC, Tauber J, et al. Phase III safety evaluation of cyclosporine 0.1% ophthalmic emulsion administered twice daily to dry eye disease patients for up to 3 years. Ophthalmology. 2005;112(10):1790–1794. doi:https://doi.org/10.1016/j.ophtha.2005.05.013.
- Dastjerdi MH, Hamrah P, Dana R. High-frequency topical cyclosporine 0.05% in the treatment of severe dry eye refractory to twice-daily regimen. Cornea. 2009;28(10):1091. doi:https://doi.org/10.1097/ICO.0b013e3181a16472.
- Malta JB, Soong HK, Shtein RM, et al. Treatment of ocular graft-versus-host disease with topical cyclosporine 0.05%. Cornea. 2010;29(12):1392–1396. doi:https://doi.org/10.1097/ICO.0b013e3181e456f0.
- Boynton GE, Raoof D, Niziol LM, et al. Prospective randomized trial comparing efficacy of topical loteprednol etabonate 0.5% versus cyclosporine-A 0.05% for treatment of dry eye syndrome following hematopoietic stem cell transplantation. Cornea. 2015;34(7):725–732. doi:https://doi.org/10.1097/ICO.0000000000000436.
- Haber SL, Benson V, Buckway CJ, et al. Lifitegrast: a novel drug for patients with dry eye disease. Ther Adv Ophthalmol. 2019;11:2515841419870366. doi:https://doi.org/10.1177/2515841419870366.
- Chhabra S, Jerkins JH, Conto JE, et al. Lifitegrast ophthalmic solution for treatment of ocular chronic graft-versus-host disease. Leuk Lymphoma. 2020;61(4):869–874. doi:https://doi.org/10.1080/10428194.2019.1695049.
- Ogawa Y, Okamoto S, Mori T, et al. Autologous serum eye drops for the treatment of severe dry eye in patients with chronic graft-versus-host disease. Bone Marrow Transplant. 2003;31(7):579–583. doi:https://doi.org/10.1038/sj.bmt.1703862.
- Stenwall PA, Bergström M, Seiron P, et al. Improving the anti‐inflammatory effect of serum eye drops using allogeneic serum permissive for regulatory T cell induction. Acta Ophthalmol. 2015;93(7):654–657. doi:https://doi.org/10.1111/aos.12801.
- Abud TB, Amparo F, Saboo US, et al. A clinical trial comparing the safety and efficacy of topical tacrolimus versus methylprednisolone in ocular graft-versus-host disease. Ophthalmology. 2016;123(7):1449–1457. doi:https://doi.org/10.1016/j.ophtha.2016.02.044.
- Jung JW, Lee YJ, Yoon SC, et al. Long-term result of maintenance treatment with tacrolimus ointment in chronic ocular graft-versus-host disease. Am J Ophthalmol. 2015;159(3):519–527e1. doi:https://doi.org/10.1016/j.ajo.2014.11.035.
- Amparo F, Dastjerdi MH, Okanobo A, et al. Topical interleukin 1 receptor antagonist for treatment of dry eye disease: a randomized clinical trial. JAMA Ophthalmol. 2013;131(6):715–723. doi:https://doi.org/10.1001/jamaophthalmol.2013.195.
- Ogawa Y, Dogru M, Uchino M, et al. Topical tranilast for treatment of the early stage of mild dry eye associated with chronic GVHD. Bone Marrow Transplant. 2010;45(3):565–569. doi:https://doi.org/10.1038/bmt.2009.173.
- Kheirkhah A, Di Zazzo A, Satitpitakul V, et al. A pilot randomized trial on safety and efficacy of a novel topical combined inhibitor of Janus kinase 1/3 and spleen tyrosine kinase for GVHD-associated ocular surface disease. Cornea. 2017;36(7):799–804. doi:https://doi.org/10.1097/ICO.0000000000001206.
- Sosne G, Ousler GW. Thymosin beta 4 ophthalmic solution for dry eye: a randomized, placebo-controlled, Phase II clinical trial conducted using the controlled adverse environment (CAE™) model. Clin Ophthalmol. 2015;9:877.
- Inamoto Y, Sun Y-C, Flowers MED, et al. Bandage soft contact lenses for ocular graft-versus-host disease. Biol Blood Marrow Transplant. 2015;21(11):2002–2007. doi:https://doi.org/10.1016/j.bbmt.2015.07.013.
- Jacobs DS, Rosenthal P. Boston scleral lens prosthetic device for treatment of severe dry eye in chronic graft-versus-host disease. Cornea. 2007;26(10):1195–1199. doi:https://doi.org/10.1097/ICO.0b013e318155743d.
- Peric Z, Skegro I, Durakovic N, et al. Amniotic membrane transplantation—a new approach to crossing the HLA barriers in the treatment of refractory ocular graft-versus-host disease. Bone Marrow Transplant. 2018;53(11):1466–1469. doi:https://doi.org/10.1038/s41409-018-0140-6.
- Balaram M, Rashid S, Dana R. Chronic ocular surface disease after allogeneic bone marrow transplantation. Ocul Surf. 2005;3(4):203–210. doi:https://doi.org/10.1016/S1542-0124(12)70207-0.
- Dietrich-Ntoukas T, Cursiefen C, Westekemper H, et al. Diagnosis and treatment of ocular chronic graft-versus-host disease: report from the German–Austrian–Swiss Consensus Conference on Clinical Practice in Chronic GVHD. Cornea. 2012;31(3):299–310. doi:https://doi.org/10.1097/ICO.0b013e318226bf97.
- Yen P-T, Hou Y-C, Lin W-C, et al. Recurrent corneal perforation and acute calcareous corneal degeneration in chronic graft-versus-host disease. JFormos Med Assoc. 2006;105(4):334–339. doi:https://doi.org/10.1016/S0929-6646(09)60125-X.
- Di Zazzo A, Kheirkhah A, Abud TB, et al. Management of high-risk corneal transplantation. Surv Ophthalmol. 2017;62(6):816–827. doi:https://doi.org/10.1016/j.survophthal.2016.12.010.
- Busin M, Giannaccare G, Sapigni L, et al. Conjunctival and limbal transplantation from the same living-related bone marrow donor to patients with severe ocular graft-vs-host disease. JAMA Ophthalmol. 2017;135(10):1123–1125. doi:https://doi.org/10.1001/jamaophthalmol.2017.3204.
- Saboo US, Amparo F, Shikari H, et al. Prevalence of ocular hypertension and glaucoma in patients with chronic ocular graft-versus-host disease. Graefe’s Archive for Clinical and Experimental Ophthalmology. 2016;254(5):923–928. doi:https://doi.org/10.1007/s00417-016-3312-3.
- Saboo US, Amparo F, Shikari H, et al. Outcomes of phacoemulsification in patients with chronic ocular graft-versus-host disease. Graefes Arch Clin Exp Ophthalmol. 2015;253(6):901–907. doi:https://doi.org/10.1007/s00417-015-2940-3.
- Inagaki E, Ogawa Y, Matsumoto Y, et al. Four cases of corneal perforation in patients with chronic graft-versus-host disease. Mol Vis. 2011;17:598.
- Bonini S, Lambiase A, Rama P, et al. Phase II randomized, double-masked, vehicle-controlled trial of recombinant human nerve growth factor for neurotrophic keratitis. Ophthalmology. 2018;125(9):1332–1343. doi:https://doi.org/10.1016/j.ophtha.2018.02.022.